ABBV · News · 20261114N

Product / Drug Pipeline Progress

AbbVie Inc. · 2026-11-14 · Importance 17 · Surprise 24

Brise Pharmaceuticals reported progress on two preclinical migraine programs licensed exclusively to AbbVie, meeting several near-term milestones. The programs add early-stage assets to AbbVie’s neuroscience and migraine pipeline. Brise bears early discovery risk, while AbbVie retains global development and commercial control.

Key facts